MARK2 and melanoma: Activation of AhR triggers the expression of gene resistance to inhibitors of the mutant proto-oncogene V600 B-Raf and serine-threonine kinase in melanoma, and an increase in the expression of apoptosis protein 1 (PD-1) in T cells infiltrating tumors that surround the melanoma.